Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H1 2018

  • ID: 4482741
  • Report
  • 69 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • Amgen Inc
  • Bioleaders Corp
  • F. Hoffmann-La Roche Ltd
  • PeptiDream Inc
  • Pfizer Inc
  • MORE
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H1 2018

Summary:

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.

The latest report GrowthDifferentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H1 2018, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGFß) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 1 and 7 respectively. Report covers products from therapy areas Genetic Disorders, Musculoskeletal Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders and Oncology which include indications Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Sarcopenia, Anemia, Becker Muscular Dystrophy, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type I, Crohn's Disease (Regional Enteritis), Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Insulin Resistance, Myelodysplastic Syndrome, Myelofibrosis, Sickle Cell Disease, Spinal Muscular Atrophy (SMA) and Thalassemia.

Furthermore, this report also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
  • The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • Amgen Inc
  • Bioleaders Corp
  • F. Hoffmann-La Roche Ltd
  • PeptiDream Inc
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development

Acceleron Pharma Inc

Amgen Inc

Bioleaders Corp

F. Hoffmann-La Roche Ltd

PeptiDream Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Sarepta Therapeutics Inc

Scholar Rock Inc

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles

ACE-083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACE-2494 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACE-2798 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATA-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLS-ILB-MD1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

domagrozumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

luspatercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-2477 + trevogrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRK-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talditercept alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trevogrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones

Featured News & Press Releases

Feb 28, 2018: Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve

Feb 08, 2018: Acceleron Announces Appointment of Chief Commercial Officer

Feb 02, 2018: Scholar Rock Announces Publication of Comprehensive Pharmacological Study of SRK-015, a Novel Inhibitor of Myostatin Activation, Supporting the Treatment of Muscle Atrophy Disorders

Jan 23, 2018: Scholar Rock and Collaborators at Harvard Medical School and Northeastern University Elucidate Molecular Basis of Myostatin Activation - a Key Physiological Process in Muscle Health

Jan 08, 2018: Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy

Dec 10, 2017: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology

Nov 01, 2017: Acceleron to Present Clinical Presentations on Investigational Drug Candidate Luspatercept at 59th American Society of Hematology Annual Meeting and Exposition

Sep 19, 2017: Acceleron Provides Clinical Update on Luspatercept at 2017 R&D Day

Sep 19, 2017: Acceleron Provides Clinical Update on Muscular Dystrophy Drug Candidate ACE-083 at 2017 R&D Day

Sep 19, 2017: Acceleron Provides Update on Clinical Development Plans for ACE-2494 at 2017 R&D Day

Sep 14, 2017: Scholar Rock Announces Issuance of Broad Patent Covering Therapeutic Approach for Neuromuscular Diseases

Sep 05, 2017: Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology

Aug 01, 2017: Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease

Jul 10, 2017: Scholar Rock and the Miami Project to Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential of SRK-015 in Spinal Cord Injury at 35th Annual National Neurotrauma Symposium

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Acceleron Pharma Inc, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Bioleaders Corp, H1 2018

Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Pipeline by PeptiDream Inc, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Pipeline by Sarepta Therapeutics Inc, H1 2018

Pipeline by Scholar Rock Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acceleron Pharma Inc
  • Amgen Inc
  • Bioleaders Corp
  • F. Hoffmann-La Roche Ltd
  • PeptiDream Inc
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Sarepta Therapeutics Inc
  • Scholar Rock Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll